Lead foreign bodies in joint spaces, often due to projectiles such as bullets, may cause localized arthropathy. There are no reports of joint fracture related to lead arthropathy. Additionally, lead foreign bodes embedded in the joint space may be a source of systemic lead absorption, causing elevated blood lead levels and toxicity to other organs. We present a young adult patient with retained left hip joint bullet fragments who developed suspected lead arthropathy and subsequent acute left hip fracture, as well as systemic lead absorption demonstrated by elevated blood lead levels. L ead toxicity is the most common cause of heavy metal poisoning. Historically, common sources of lead toxicity have varied, but internally sequestered lead from traumatic projectiles remains a consistent concern. Lead projectiles lodged within joint spaces from gunshot wounds and explosive devices may cause localized joint damage, known as lead arthropathy. Additionally, systemic lead toxicity may occur as solubilized lead gains access to the circulation through the damaged joint. Systemic lead toxicity symptoms vary widely by organ system involved, but may prompt consideration for surgical removal of the lead source and lead chelation therapy. We discuss a patient with bullet lead arthropathy, subsequent fracture of the involved joint, and evidence of systemic lead absorption.
CASE DESCRIPTION
A 32-year-old man was previously evaluated at our hospital for a gunshot wound to the right buttock, which crossed midline and lodged in the subcutaneous tissue of the left proximal thigh. Initial imaging demonstrated fractures of the left posterior acetabulum and coccyx, a large bullet fragment in the left subcutaneous thigh, and tiny bullet fragments overlying the left hip joint ( Figure 1 a) . Th e fractures were nonoperative. Traumatic sequelae included left hip pain, left sciatic neuropathy, decreased sensation to the left S1 dermatome, and left foot drop. Th e left thigh bullet was removed without incident 1 week later.
Four months after the injury, the patient presented with acute-on-chronic left leg pain. Radiographs demonstrated left hip ( Figure 1 b) Th e patient presented again to the emergency department 1 month later for acute-on-chronic left leg pain. Additionally, the patient complained of recent-onset nausea, anorexia, and constipation. Th e blood hemoglobin was 13.2 g/dL (normal, 14-18). Eight months after the gunshot wound, the patient presented to our emergency department with increasing left hip pain after a reported seizure 2 days earlier. He had no new hip trauma. Th e patient reported only a remote seizure many years ago. He reported no other new symptoms. Imaging of the left hip demonstrated an acute displaced subcapital femoral neck fracture, along with the old, stable acetabular fracture and retained hip bullet fragments ( Figure 1 c) . Th e patient underwent open reduction internal fi xation with hip screw placement. Despite multiple patient contact attempts, we were unable to assess further symptoms of lead toxicity or arrange for repeat lead levels.
DISCUSSION
Lead toxicity is the most common form of heavy metal poisoning. Signifi cant lead exposure may occur through occupational sources, such as battery processing, car radiators, glassmaking, brass-making, and de-leading of older facilities with lead-containing paint. Ingestion of lead-containing substances may occur in children exposed to paint chips in older housing. Toxicity may result from internal exposure of lead-containing foreign bodies, such as lead-containing bullets, buckshot, fi shing sinkers, and some herbal preparations ( 1, 2 ) .
Lead sources that embed in the joint space, such as bullets and buckshot, are often introduced traumatically. Normally, lead foreign bodies in the soft tissue are encapsulated by an immune-mediated fibrous reaction, limiting adjacent and systemic lead exposure. However, lead foreign bodies in the joint space may cause localized tissue destruction, known as lead arthropathy, and in some cases may be a source for leaking of lead into the systemic circulation ( 3, 4 ) .
Lead arthropathy has been associated with localized degenerative joint disease, synovitis, and gout ( 5, 6 ) . Degenerative joint disease may develop secondary to interaction of both irregular joint surfaces from fractures and from intraarticular bone and lead fragments sustained during the initial injury ( 5, 7 ). Our patient's initial injury resulted in left acetabular fracture with associated joint bullet fragments. Later x-rays showed signs of arthropathy, likely due to both lead and posttraumatic etiologies. Subsequently, the patient sustained a new, acute left subcapital femoral neck fracture after a reported seizure. Th ere were no reported signs of external left hip trauma to suggest another precipitant for hip fracture. Th ere were no other known metabolic or structural risk factors for fracture. Th erefore, it is reasonable to suggest the acute left hip fracture was precipitated by preexisting lead and posttraumatic joint arthropathy. We were unable to locate previous reports of fracture directly associated with lead arthropathy.
In addition, systemic absorption of lead from the joint space may occur due to multiple factors. Mechanical fragmentation of implanted lead projectiles, in addition to the acidic synovial fl uid, increases lead solubilization. Absorption of lead through an infl amed synovium introduces lead into the systemic circulation ( 3 -5, 7, 8 ) . Subsequent systemic lead toxicity symptoms may occur as soon as weeks after, but more typically symptoms manifest years or decades following the ( 3, 5, 7, 8 ) . Symptoms of lead toxicity vary by organ system ( Table 1 ) . Evaluation for systemic lead toxicity was diffi cult in our patient due to multiple unplanned hospital visits with diff erent providers and lack of follow-up. Th e patient presented on diff erent occasions with nonspecifi c complaints and a reported seizure. Th ere was no reported ongoing mental status change to strongly suggest worsening nervous system lead toxicity. However, retained joint foreign bodies in such patients may possibly contribute to developing systemic lead toxicity in the future. Blood lead level measurements are an important variable in treatment of lead toxicity. However, they do not always correlate with severity of toxicity. A blood lead level >10 mcg/dL in adults and >5 mcg/dL in children is considered elevated ( 9, 10 ) . However, adults and children may not show clinical signs or symptoms until blood lead levels are >70 mcg/dL in adults and >45 mcg/dL in children ( 11 ) . Central nervous system (CNS) manifestations, such as encephalopathy, are rare, but occur in toddlers aged 15 to 30 months with blood lead levels >100 mcg/ dL. However, similar eff ects in this age group may occur with blood lead levels ≤70 mcg/dL ( 11 ) .
When blood lead levels are not available, lead toxicity may be considered presumptively based on a history of lead exposure, the presence of anemia, and radiographic evidence of lead. Black-blue lines (Burton's line) may be seen on gums in chronic lead toxicity. Anemia, which may be microcytic or normocytic, is often present with or without basophilic stippling. Hemolytic anemia may be present. Blood chemistries, creatinine level, liver function tests, and urinalysis should be assessed for toxic effects and in preparation for possible chelation therapy options ( 1, 9, (11) (12) (13) .
Radiographic diagnosis of lead arthropathy involves manifestations of the initial traumatic insult and subsequent sequelae ( 7, 14 ) . Possible radiographic identifi cation includes evidence of joint eff usion, synovial thickening, synovial deposition of lead particles, lead arthrogram, joint space narrowing, evidence of metallic particles present in the tendon sheaths of aff ected joints, and lead arthrogram where the entire joint cavity can be outlined by lead ( 3, 8 ) . Joint eff usion, synovial thickening, synovial lead particle deposition, lead arthrogram, and joint space narrowing are the most frequently manifested radiographic fi ndings ( 3, 8 ) . X-rays in children with a history of heavy lead exposure may have increased metaphyseal density of long bones (lead lines) ( 11, 12 ) .
Treatment for lead toxicity includes removal of/from the lead source and, if indicated, lead chelation therapy. Due to the known possibility of joint pathology and systemic lead toxicity, all cases of lead arthropathy should be considered for removal of the source of lead exposure, unless it is embedded in soft tissue and not exposed to body fl uids or is adjacent to neurovascular structures. An orthopedic surgery consultation is needed for consideration of removal of the joint space lead products, usually by synovectomy or arthroplasty. In addition, lead chelation therapy should be considered. Lead chelation therapy with dimercaprol plus edetate calcium disodium is indicated for lead toxicity with severe CNS symptoms, such as encephalopathy, irrespective of blood lead level. CNS lead is chelated by dimercaprol (British anti-Lewisite), which is an intramuscular medication that crosses the blood-brain barrier. Edetate calcium disodium (CaNa2-EDTA), given intravenously or intramuscularly, does not cross the brain barrier and is used concurrently to chelate lead outside of the CNS ( 13, 15 ) . Importantly, edetate disodium, used for hypercalcemia treatment, should not be mistakenly ordered instead of edetate calcium disodium, as it may cause life-threatening hypocalcemia.
Chelation therapy for lead toxicity that does not include severe CNS toxicity should be considered for symptomatic adults with a lead level >100 mcg/dL and symptomatic children with a lead level >69 mcg/dL, and possibly for asymptomatic adults with a lead level >70 mcg/dL and asymptomatic children with a lead level of >45 mcg/dL ( 11 ) . Chelating agents for non-CNS system toxicity include dimercaprol plus edetate calcium disodium, succimer, or d-penicillamine ( 3, 4 ) . As with lead encephalopathy, dimercaprol and edetate calcium disodium are used as combination therapy. Edetate calcium disodium is generally not recommended as a solo therapy due to its inability to bind newly mobilized yet not chelated lead entering the CNS, which may lead to encephalopathy. Alternatively, succimer, an oral analog of dimercaprol, may be used as a solo lead chelating agent for 2 to 3 weeks ( 6, 15 ). Finally, d-penicillamine is considered a third-line agent for lead poisoning by the American Academy of Pediatrics ( 10, 14 ) . Ascorbic acid may be helpful in reducing serum lead levels ( 2, 12 ) . Patients who are asymptomatic and have low blood lead levels (adults <90 mcg/dL and children <45 mcg/dL) are treated by removal of the lead source alone, without chelation therapy. Ultimately, consultation with a toxicology specialist is recommended for consideration of lead chelation therapy. Generally, patients should be admitted to the hospital for initial chelation therapy.
